Revvity Q1 revenue rises 7% to $711 million; adjusted EPS $1.06 vs $1.01 a year earlier
Revvity reported first-quarter 2026 revenue of $711 million, up from $665 million a year earlier, and adjusted EPS of $1.06, up from $1.01. The company also said it intends to divest its China Immunodiagnostics business, under a letter of intent for up to $200 million, and updated its full-year 2026 guidance on a pro forma basis.
Key points
- Q1 2026 revenue was $711 million vs $665 million a year earlier; GAAP EPS from continuing operations was $0.37 vs $0.35.
- Adjusted operating income was $168 million vs $170 million, and adjusted operating margin was 23.6% vs 25.6%.
- Full-year 2026 pro forma guidance: total revenue of $2.81-$2.84 billion and pro forma adjusted EPS of $5.20-$5.30.
- China Immunodiagnostics was about 6% of 2025 revenue; a letter of intent was signed April 16, 2026, with a definitive agreement expected in Q2 2026 and completion expected in 2027.
The filing
Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.